{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T02:36:20Z","timestamp":1790217380556,"version":"4.1.0"},"reference-count":22,"publisher":"BMJ","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Ophthalmol"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1136\/bjophthalmol-2012-302276","type":"journal-article","created":{"date-parts":[[2012,12,8]],"date-time":"2012-12-08T22:25:34Z","timestamp":1355005534000},"page":"816-819","source":"Crossref","is-referenced-by-count":77,"title":["Short-term outcome after intravitreal ranibizumab injections for the treatment of retinopathy of prematurity"],"prefix":"10.1136","volume":"97","author":[{"given":"Mar\u00eda Ana Mart\u00ednez","family":"Castellanos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shulamit","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerardo","family":"Garc\u00eda-Aguirre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Quiroz-Mercado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2012,12,8]]},"reference":[{"key":"key-10.1136\/bjophthalmol-2012-302276-1","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.ajo.2009.04.018","article-title":"Incidence of retinopathy of prematurity in the United States: 1997 through 2005","volume":"148","author":"Lad","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2012-302276-2","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.earlhumdev.2007.11.009","article-title":"Retinopathy of prematurity: a global perspective of the epidemics, population of babies at risk and implications for control","volume":"84","author":"Gilbert","year":"2008","journal-title":"Early Hum Dev"},{"key":"key-10.1136\/bjophthalmol-2012-302276-3","doi-asserted-by":"crossref","first-page":"5177","DOI":"10.1167\/iovs.08-2584","article-title":"Through the eyes of a child: understanding retinopathy through ROP","volume":"49","author":"Smith","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"key-10.1136\/bjophthalmol-2012-302276-4","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1016\/j.ophtha.2005.09.018","article-title":"Growth factor levels and ROP","volume":"112","author":"Villegas","year":"2005","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2012-302276-5","first-page":"290","article-title":"Roles of vascular endothelial growth factor and astrocyte degeneration in the genesis of retinopathy of prematurity","volume":"37","author":"Stone","year":"1996","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"key-10.1136\/bjophthalmol-2012-302276-6","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1001\/archopht.1988.01060130517027","article-title":"Multicenter trial of cryotherapy for retinopathy of prematurity: preliminary results","volume":"106","author":"Cryotherapy for Retinopathy of Prematurity Cooperative Group","year":"1988","journal-title":"Arch Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2012-302276-7","first-page":"233","article-title":"Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial","volume":"102","author":"Good","year":"2004","journal-title":"Trans Am Ophthalmol Soc"},{"key":"key-10.1136\/bjophthalmol-2012-302276-8","doi-asserted-by":"crossref","first-page":"852183","DOI":"10.1155\/2012\/852183","article-title":"Anti-VEGF agents for ocular angiogenesis and vascular permeability","volume":"2012","author":"Kimoto","year":"2012","journal-title":"J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2012-302276-9","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1097\/IAE.0b013e318159ec6b","article-title":"Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity","volume":"28","author":"Quiroz-Mercado","year":"2008","journal-title":"Retina"},{"key":"key-10.1136\/bjophthalmol-2012-302276-10","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1097\/IAE.0b013e3181644ad2","article-title":"Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity","volume":"28","author":"Lalwani","year":"2008","journal-title":"Retina"},{"key":"key-10.1136\/bjophthalmol-2012-302276-11","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1080\/08820530701420082","article-title":"Our experience after 1765 intravitreal injections of bevacizumab: the importance of being part of a developing story","volume":"22","author":"Quiroz-Mercado","year":"2007","journal-title":"Semin Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2012-302276-12","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N Engl J Med"},{"key":"key-10.1136\/bjophthalmol-2012-302276-13","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1159\/000338623","article-title":"Combination of intravitreal ranibizumab and laser photocoagulation for aggressive posterior retinopathy of prematurity","volume":"3","author":"Mota","year":"2012","journal-title":"Case Report Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2012-302276-14","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1001\/archopht.123.7.991","article-title":"The International Classification of Retinopathy of Prematurity revisited","volume":"123","author":"International Committee for the Classification of Retinopathy of Prematurity","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2012-302276-15","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1136\/bjophthalmol-2011-300015","article-title":"Retinopathy of prematurity as a major cause of severe visual impairment and blindness in children in schools for the blind in Guadalajara city, Mexico","volume":"95","author":"Zepeda-Romero","year":"2011","journal-title":"Br J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2012-302276-16","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","article-title":"Revised indications for the treatment of retinopathy of prematurity: results of the Early Treatment for Retinopathy of Prematurity randomized trial","volume":"121","author":"Early Treatment for Retinopathy of Prematurity Cooperative Group","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2012-302276-17","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/bjo.81.1.12","article-title":"Cryotherapy and laser treatment for acute retinopathy of prematurity: refractive outcomes, a longitudinal study","volume":"81","author":"Laws","year":"1997","journal-title":"Br J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2012-302276-18","first-page":"76","article-title":"UK retinopathy of prematurity treatment survey","volume":"7","author":"Cuthbertson","year":"2006","journal-title":"Eye"},{"key":"key-10.1136\/bjophthalmol-2012-302276-19","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.ajo.2009.05.031","article-title":"A systematic analysis of the off-label use of bevacizumab for severe retinopathy of prematurity","volume":"148","author":"Micieli","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2012-302276-20","article-title":"Are we there yet? Bevacizumab therapy for retinopathy of prematurity","author":"Darlow","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"key-10.1136\/bjophthalmol-2012-302276-21","article-title":"Pain assessment in premature infants treated with intravitreal antiangiogenic therapy for retinopathy of prematurity under topical anesthesia","author":"Castellanos","year":"2012","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2012-302276-22","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.ophtha.2009.06.045","article-title":"Introduction: Understanding the role of angiogenesis and antiangiogenic agents in age-related macular degeneration","volume":"116","author":"Bressler","year":"2009","journal-title":"Ophthalmology"}],"container-title":["British Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bjophthalmol-2012-302276","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T04:42:41Z","timestamp":1601095361000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjo.bmj.com\/lookup\/doi\/10.1136\/bjophthalmol-2012-302276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12,8]]},"references-count":22,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2013,6,12]]},"published-print":{"date-parts":[[2013,7]]}},"alternative-id":["10.1136\/bjophthalmol-2012-302276"],"URL":"https:\/\/doi.org\/10.1136\/bjophthalmol-2012-302276","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717970380.793469011","asserted-by":"object"}]},"ISSN":["0007-1161","1468-2079"],"issn-type":[{"value":"0007-1161","type":"print"},{"value":"1468-2079","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12,8]]}}}